Key result
Thrombin inhibitors, including heparin and antithrombin III, inhibited the thrombin-induced platelet reaction, though heparin did not potentiate the inhibition by antithrombin III.
In an in vitro model using human blood platelets, heparin and antithrombin III inhibit thrombin-induced platelet activation, though heparin does not potentiate the effect of antithrombin III.
Answers are grounded in this paper and cite their sources.
These in vitro findings should not change clinical anticoagulation; leaves open thrombin-platelet mechanisms for in vivo study.
The influence of thrombin inhibitors, which differ both in their chemical structure and type of inhibition, on the thrombin-platelet reaction was studied. The inhibitory effects of the competitive inhibitors tested on the thrombin-induced platelet reaction correlated well with their effects on the thrombin-catalyzed fibrinogen conversion and on the thrombin-catalyzed hydrolysis of synthetic substrates. Heparin and antithrombin III inhibited the thrombin-induced platelet reaction. However, heparin did not potentiate the inhibition by antithrombin III of the thrombin-platelet reaction.
No takes yet. Share an insight, caveat, or question.
Markwárdt et al. (2009) studied this question. Thrombin inhibitors (including heparin and antithrombin III) was evaluated on Thrombin-induced platelet reaction. Thrombin inhibitors, including heparin and antithrombin III, inhibited the thrombin-induced platelet reaction, though heparin did not potentiate the inhibition by antithrombin III.
Synapse has enriched 10 related papers. Consider them for comparative context: